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ABSTRACT
Objectives: Irritable bowel syndrome (IBS) is the most prevalent functional bowel disorder
which is characterized by chronic abdominal pain and altered bowel habit in the absence of any
organic disease. This study examined the effects of “relaxation and citalopram” in comparison
to “citalopram” alone on alleviating the symptoms of IBS patients with diarrhea predominance.
Methodology: This study was a randomized clinical trial which included 64 IBS patients. The
patients were selected according to Rome-III criteria, and were divided into two groups. Bowel
Symptoms Severity and Frequency Scale (BSS-FS) was used for evaluation of the patients’
symptoms. Data was analyzed using analysis of covariance (ANCOVA).
Results: There were significant differences in the severity and frequency of IBS symptoms
between two groups after the study period regarding BSS-FS (P < 0.05). However, no significant
difference was observed at follow-up stage between two groups (P > 0.05).
Conclusion: Relaxation in addition to citalopram in IBS patients with diarrhea predominance
can decrease the severity and frequency of symptoms. However, stopping this treatment may
lead to recurrence of the symptoms.
KEY WORDS: Irritable bowel syndrome, Relaxation, Citalopram, Bowel Symptoms Severity and
Frequency Scale (BSS-FS).
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INTRODUCTION
Irritable Bowel Syndrome (IBS) is a functional
bowel disorder in which abdominal pain or dis-
comfort is associated with defecating or a
change in bowel habit and features of disor-
dered defecation.1 IBS is mainly a disorder of
young people, with most new cases presenting
before the age of 45.2 Women are diagnosed with
IBS two to three times as often as men.3-5 Stud-
ies indicate that approximately 50-90% of pa-
tients seeking treatment for IBS meet criteria for
a psychiatric disorder. The psychiatric disorders
include major depressive disorder, general
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anxiety disorder, panic disorder, social phobia,
somatization disorder, and post traumatic stress
disorder.5 About 55% of IBS patients have pre-
sented with an axis I psychiatric disorder,6 and
40-80% of patients reported psychiatric
symptoms prior to the onset of gastrointestinal
symptoms.7
Psychological treatments and the efficacy of
antidepressants are considered to be useful in
IBS, although the evidence is based on small,
often flawed trials and is controversial.8-10 Re-
laxation therapy or multimodal therapy (a com-
bination of relaxation therapy, education and
psychotherapy) is beneficial for IBS.11 In a study
the effect of “breathing exercises” and identifi-
cation of life stress was compared to pharma-
cological treatment with antispasmodic
Colpermin in IBS patients. The results indicated
that the group which received stress manage-
ment reported fewer and less severe gastrointes-
tinal attacks than the pharmacotherapy group.
The authors considered the treatment to be more
helpful at a 6-month follow-up.12
Studies of citalopram and amitriptyline in IBS
symptoms also have shown that these drugs
significantly improve IBS symptoms, including
abdominal pain, bloating compared with
placebo.13, 14
The results of a study which examined the
effects of relaxation response meditation on the
symptoms of IBS,  showed significant improve-
ment in the relaxation response meditation
condition when compared to the wait list
symptom monitoring condition.15 In another
review study which evaluated complementary
and alternative medicine for treatment of IBS,
it was noted that several complementary and
alternative therapies (relaxation and hypno-
therapy) can be recommended as part of an evi-
dence-based approach to the treatment of IBS.16
The aim of this study was to examine the
effect of relaxation with citalopram in the
frequency and severity of IBS symptoms.
METHODOLOGY
This study was carried out as a clinical trial.
Study population consisted of all patients with
gastrointestinal complaints of Esfahan province
who presented to Psychosomatic Clinic of Noor
Hospital. Following examination by a gastro-
enterologist and using diagnostic criteria of
Rome-III, 64 cases with IBS diagnosis who had
diarrhea as their dominant symptom were
selected. The patients were divided into two
groups each one consisted of 32 patients.
The first group underwent relaxation with
medication therapy, and the second group only
received medication. The duration of treatment
was two months. Relaxation therapy included
eight sessions once weekly. The medication
used was citalopram (a selective serotonin
reuptake inhibitor (SSRI)) which was adminis-
tered for both groups. Citalopram was initiated
with the dosage of 10 mg daily and was in-
creased to 40 mg daily after three weeks. We
used Bowel Symptoms Severity and Frequency
Scale (BSS-FS) which was designed by gastro-
enterologists according to Rome-III criteria. This
scale contains five questions about frequency
and five questions about the severity of bowel
symptoms. It measures the symptoms of IBS
patients with diarrhea as dominant symptom
(IBS-D). The scoring of this scale was propor-
tional to the severity and frequency of symp-
toms in Likert scale (0-4). This test was done in
three stages; the first stage before therapeutic
interventions, the second stage after therapeu-
tic interventions, and the third stage was three
months after the last interventions or follow-
up. This questionnaire was experimented in 30
patients via a pilot study during two weeks that
yielded correlation in two experiments was 0.81.
Statistical method used in this study was co-
variance analysis that compared the two groups
with regard to covariate variables (pre-test and
history of illness). Levenes test results showed
that pre-assumption equivalent of covariance
of dependent variable in both groups and be-
cause of assimilation of samples in groups we
were able to use analysis of covariance
(ANCOVA).
RESULTS
The average age of patients was 33 years.
Twenty-four patients were male and 40 were
female. Fifty patients were married and 14 were
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single. Most of them had high school diploma
(37.5% in relaxation group and 31.25% in drug
group). Most of patients were suffering from IBS
between 5 to 9 years; 46.8% of patients in relax-
ation group and 50% in drug group. There
wasn’t any correlation between demographic
characteristics and pre-testing scores of BSS-FS.
But there was correlation between illness
history and pre-testing scores of BSS-FS.
Comparing the differences between the two
studied groups in terms of dependent variables
showed that there was a significant difference
between “relaxation group” and “citalopram
with relaxation group” in Bowel Symptoms Fre-
quency Scale (BSFS) in post-test stage. However,
there was no significant difference at follow-up
stage (Table-I); (P = 0.001 vs. P = 0.88).
There was significant difference regarding
means of Bowel Symptoms Severity Scale (BSSS)
between two studied groups in post–test stage,
but the difference was not significant at follow-
up stage (Table-II); (P = 0.007 vs. P = 0.13).
DISCUSSION
Psychotherapy and anti-depression drugs
have been demonstrated to be useful in sever
IBS symptoms.10 Although SSRIs are used for
IBS, there is not consistent evidence for its ef-
fects.9,13,17 It is estimated that in 50-90% of IBS
patients, a psychiatric background is respon-
sible for their problems. Depression, anxiety and
somatoform disorders were reported more than
other psychological problems in patients suf-
fering from IBS.5 Psychotherapy is always effec-
tive for reducing the IBS symptoms.8,18,19 In some
studies, relaxation was reported as a method of
psychotherapy for decreasing functional gas-
trointestinal disorders such as bloating, belch-
ing and diarrhea.15,20 But in some other studies
relaxation wasn’t reported to be more effective
than routine clinical cares.8
Our results showed that the prevalence of IBS
in women was more common than men which
is in agreement with former researches.21, 22 The
presence of IBS history has been reported from
6 months to 22 years which shows that IBS is a
chronic disorder.23 The current results show that
using relaxation with drug therapy was more
useful than using only drug therapy for decreas-
ing BSFS in IBS patients which was supported
by a statistical significant difference. So we sug-
gest that it is better to use psychological inter-
vention along with pharmacotherapy.
ANCOVA results showed that there were sig-
nificant differences between studied groups in
severity and frequency of symptoms at post-
testing stage but there wasn’t significant differ-
ence at follow-up stage. Some investigators ac-
cept that using anti-depression drugs (for ex-
ample citalopram and amitriptyline) are useful
for reducing the severity and frequency of
symptoms in IBS patients.13,14,24 In contrast, some
other studies have not reported such a benefi-
cial effect and claim that the effect of anti-de-
pression drugs is similar to placebo.9 Using
citalopram with relaxation in post-testing stage
Table-I: ANCOVA results comparing the differences variable and control of history illness and
pre-test of BSFS in post-test and follow-up stages
Source Mean square Df       F       Sig Eta2 Observed Power
history of illness 8.64(8.75) 1(1) 5.17(4.32) 0.028* (0.035)* 0.26(0.20) 0.84(0.89)
pre-test 9.85(8.35) 1(1) 7.25(6.49) 0.008** (0.040)* 0.45(0.18) 0.92(0.81)
groups different 10.53(6.63) 1(1) 15.62(3.20) 0.001** (0.88) 0.62(0.24) 0.96(0.83)
* p<0.05.         ** p<0.01
Table-II: ANCOVA results comparing the differences variable and control of
history illness and Pre-test of BSSS in Post-test and follow-up stages
Source Mean square Df         F        Sig Eta2 Observed Power
history of illness 6.55(7.13) 1(1) 6.08 (5.72) 0.014* (0.021)* 0.31(0.28) 0.81(0.78)
pre-test 8.30(7.94) 1(1) 7.17 (6.25) 0.005** (0.027)* 0.52(0.30) 0.93(0.85)
groups different 9.66(5.04) 1(1) 12.81 (2.29) 0.007** (0.13) 0.59(0.18) 0.91(0.80)
* p<0.05.         ** p<0.01
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was more effective than using only citalopram
and the difference at this stage was statistically
significant but it was not significant at follow-
up visit. IBS symptoms were back again at fol-
low-up stage but the severity was lower than
pre-testing stage. Gradual relapse of IBS symp-
toms after 6 months has been reported in other
studies that show there wasn’t any lifelong cure
for IBS and this is a chronic disorder.25,26
In conclusion, the results of this study showed
that using anti-depression drugs with relaxation
is useful for reducing the severity and frequency
of symptoms in IBS patients. However, stopping
this treatment will lead in recurrence of symp-
toms. Therefore, presence of cooperation be-
tween gastroenterologists and psychiatrists may
have satisfactory outcomes for IBS patients.
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